Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Chinese Patent Office
Cerilliant
UBS
Farmers Insurance
Healthtrust
Argus Health
Cantor Fitzgerald

Generated: April 23, 2018

DrugPatentWatch Database Preview

Hoffmann La Roche Company Profile

« Back to Dashboard

Summary for Hoffmann La Roche
International Patents:343
US Patents:13
Tradenames:11
Ingredients:10
NDAs:13

Drugs and US Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes 8,741,920 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Hoffmann La Roche ROCEPHIN ceftriaxone sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 050585-002 Dec 21, 1984 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche ROCEPHIN ceftriaxone sodium INJECTABLE;INJECTION 063239-001 Aug 13, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-003 May 7, 1982 4,322,438 ➤ Try a Free Trial
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-004 Mar 28, 1983 4,464,394*PED ➤ Try a Free Trial
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-002 May 7, 1982 4,464,394*PED ➤ Try a Free Trial
Hoffmann La Roche VALCYTE valganciclovir hydrochloride TABLET;ORAL 021304-001 Mar 29, 2001 6,083,953*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 150 mg and 500 mg ➤ Subscribe 2008-11-10
➤ Subscribe Tablets 2.5 mg and 150 mg ➤ Subscribe 2007-05-16
➤ Subscribe For Oral Solution 50 mg/mL ➤ Subscribe 2011-03-21
➤ Subscribe Injection 1 mg/mL, 3 mL Vial ➤ Subscribe 2007-08-31
➤ Subscribe Tablets 450 mg ➤ Subscribe 2005-12-27
Premature patent expirations for HOFFMANN LA ROCHE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Hoffmann La Roche

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,329,724 Process for the manufacture of pharmaceutically active compounds ➤ Try a Free Trial
7,846,941 Compounds modulating c-kit and c-fms activity and uses therefor ➤ Try a Free Trial
8,415,469 Compounds and methods for kinase modulation, and indications therefor ➤ Try a Free Trial
6,627,221 Pharmaceutical composition containing diphosphonic acid or salt thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Hoffmann La Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012010 Lithuania ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
2, 5012-2012 Slovakia ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIB; REGISTRATION NO/DATE: EI/1/712/751/002 20120217
C/GB12/021 United Kingdom ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/12/751/001 20120221
00534 Netherlands ➤ Try a Free Trial PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Fish and Richardson
Daiichi Sankyo
Covington
Healthtrust
Medtronic
US Army
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.